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A considerable proportion of Lynch syndrome families
present with mismatch repair (MMR) gene sequence var-
iants of uncertain clinical significance, which constitute a
challenge in both the research and clinical settings. Such
unclassified variants (UVs) include rare nucleotide
changes predicted to cause missense substitutions, small
in-frame deletions, or possible alterations in splicing.
We are developing a MMR multifactorial likelihood
model to provide a quantitative measure of MMR var-
iant pathogenicity. Bayes analysis of families to measure
v a r i a n tc a u s a l i t yb ys e g r e g a t i o nm e t h o d si se s t a b l i s h e d .
Likelihood ratios for microsatellite instability and
somatic BRAF tumour status have also recently been
incorporated into the multifactorial model. We are cur-
rently estimating the prior probability of pathogenicity
for MMR missense substitutions based on the evolution-
ary conservation and physicochemical properties of
amino acid alterations. To th i se n d ,w eh a v eb u i l ta n d
curated multiple-species sequence alignments of the
four MMR proteins. In parallel, we identified 143 appar-
ent missense substitutions, excluded 12 with evidence of
causing a splice defect, and then used a combination of
quantitative and qualitative criteria to classify 73 as
either pathogenic, likely pathogenic, likely not patho-
genic, or not pathogenic, based on the IARC five-class
system. Six different missense substitution analysis tools
(Align-GVGD, MAPP, MutPred, PolyPhen-2.1, SIFT,
and Xvir) were used to score the missense substitutions.
The bioinformatic outputs are being calibrated by
regression against the classifications of the 73 missense
substitutions to estimate a prior probability of patho-
genicity for MMR missense substitutions.
In summary, we have developed a MMR classification
model including tumour characteristics, segregation ana-
lysis, and in silico prior probability of pathogenicity for
missense substitutions. This multifactorial model will be
applied to the analysis of 34 UVs from Australasian
families, for which we have already completed assess-
ment of tumour pathology, variant association with dis-
ease in families, and bioinformatic and in vitro splicing
analysis. Results from this analysis will alter the manage-
ment of these and other MMR variant-carrying families.
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